American pharmaceutical companies Moderna, Johnson & Johnson, and BioNTech, a German company that is involved in the research and development of the "Fubitai vaccine", are studying and adjusting the existing new coronavirus pneumonia (COVID-19) vaccine , So that it can prevent the mutant strain Omicron (奥米克荣).
Many pharmaceutical companies have been preparing for the adjustment of their products to deal with the possibility of new variant viruses for several months.
BioNTech, a German partner of the US pharmaceutical company Pfizer, said that if necessary, the vaccine may be developed within 100 days.
BioNTech said on the 29th that it has started research and development work.
Several initial steps in the development of a new vaccine overlap with research to assess whether a vaccine is needed.
Both BioNTech and Moderna started this procedure after South Africa announced the discovery of a new strain on Thursday (25th).
BioNTech, Pfizer and Moderna were able to take action at an unprecedented speed, mainly because both vaccines use mRNA technology, which can shorten the development time of new vaccines to several months.
Johnson & Johnson vaccine uses viral vector technology.
The company said that it is studying the blood components of people participating in the booster test to find a response to Omicron. It is also developing a vaccine specifically for Omicron, and will conduct human studies if necessary.
Many countries around the world are advancing vaccination plans, and in Omicron's view, governments and pharmaceutical companies in many countries must race against time.
The picture shows a high school student being vaccinated against the new crown pneumonia in a school in Pristina, the capital of Kosovo, on November 26, 2021.
BioNTech and Moderna separately said that within a few weeks it should be determined whether the existing vaccine needs to be adjusted.
A spokesperson said that Pfizer and its partners developed a plan to upgrade vaccines within 100 days if necessary a few months ago.
BioNTech said that while testing the effects of existing vaccines on new strains, it is a standard procedure to start developing upgraded vaccines, "so as not to waste time." "Laboratory testing will provide more information on whether the vaccine needs to be adjusted."
Paul Burton, Chief Medical Officer of Moderna, said on the BBC talk show "Andrew Marr Show" on Sunday that people who have been vaccinated can still be protected, depending on how long the vaccination has been. A good suggestion is to get an existing vaccine.
AstraZeneca said on the 26th that it is also investigating new mutant strains.
Biden: The United States will not further restrict travel or shut down the economy due to Omicron. Omicron | The first cases in Sweden and Spain are all from South Africa Omicron | Australia, Canada and other 13 countries including high-risk areas and non-Hong Kong residents are not allowed to enter Omicron: the United Kingdom and Portugal suspects that there have been local cases in Britain, the United States, Australia and Canada
Pfizer CEO Albert Bourla believes that it is still difficult to predict the impact of Omicron on the protection of the vaccine, but it is impossible to cause it to completely lose its protection.
Bla said that the company's scientists had produced the first DNA template on the 26th, saying that he was confident that a vaccine against Omicron would be produced within 100 days.